Abbott Neuromodulation

Abbott Neuromodulation is a division of Abbott Laboratories headquartered in Austin, Texas, focused on developing implantable neurostimulation therapies for patients living with chronic pain and movement disorders. The division's portfolio spans spinal cord stimulation, deep brain stimulation, and dorsal root ganglion therapies, delivered through flagship products such as the Proclaim DRG Neurostimulator and the Infinity DBS System. Central to their pain management offering is BurstDR stimulation, a proprietary waveform technology designed to more closely mimic the brain's natural neural firing patterns. This approach has been clinically demonstrated to provide superior chronic pain relief compared to conventional tonic stimulation, representing a meaningful advancement in how neuromodulation devices interact with the nervous system.

As a publicly traded entity under NYSE: ABT, Abbott brings the financial scale and global infrastructure of a major medical device company to the neuromodulation space, enabling broad commercialization and sustained investment in clinical research. The Infinity DBS System is notable for its directional lead technology, which allows clinicians to steer stimulation fields with greater precision and reduce unwanted side effects in patients with Parkinson's disease and other movement disorders. Abbott's BurstDR platform has accumulated a substantial body of clinical evidence, including data from the SUNBURST randomized controlled trial, which established its efficacy over traditional stimulation paradigms. These milestones have solidified Abbott's standing as one of the leading commercial players in the global neuromodulation market alongside competitors such as Medtronic and Boston Scientific.

Abbott Neuromodulation matters to the broader neurotech industry because it demonstrates the clinical and commercial viability of next-generation stimulation paradigms at scale. By investing in biologically informed waveform design and precision targeting technologies, the division has helped shift the field's expectations around what implantable neurostimulators can achieve for patients. Their work on dorsal root ganglion stimulation has also opened a distinct therapeutic pathway for localized chronic pain conditions that were historically difficult to treat with conventional spinal cord stimulation. As neuromodulation continues to expand into new indications, Abbott's combination of clinical rigor, regulatory experience, and global reach positions the division as an influential force shaping the trajectory of the industry.